Connection
Kole DeGolier to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Kole DeGolier has written about Xenograft Model Antitumor Assays.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.229 |
|
|
|
-
DeGolier KR, Pham-Danis C, Burciaga SD, Walsh ZH, Brzezinski C, Novak AJ, Leach L, Cimons J, Li W, Zhongyu Z, Dimitrov D, Scott-Browne JP, Kohler ME, Fry TJ. Rational redesign of antigen binding domain improves in vivo efficacy of the CD22-CAR. Mol Ther. 2026 Apr 01; 34(4):2175-2188.
Score: 0.185
-
Cimons JM, DeGolier KR, Burciaga SD, Yarnell MC, Novak AJ, Rivera-Reyes AM, Kohler ME, Fry TJ. T-bet overexpression enhances CAR T cell effector functions and antigen sensitivity. J Immunother Cancer. 2025 Apr 17; 13(4).
Score: 0.044